

QUICK USER GUIDE – DATA SUBMISSION

Target: BP™ • Check. Change. Control. Cholesterol™ • Target: Type 2 DiabetesSM

This guide provides instructions for registering and submitting data for achievement awards in any of the three outpatient quality improvement initiatives:

- <u>Target: BP™</u>
- Check. Change. Control. Cholesterol™
- Target: Type 2 DiabetesSM

Table of Contents

Getting Started	1
Troubleshooting and Support	2
Navigating the Online Platform	2
Entering Data – Adding Your Program Forms	3
Entering Data – Target: BP™	5
Entering Data – Check. Change. Control. Cholesterol™	10
Entering Data – Target: Type 2 Diabetes sm	17

Getting Started

If your organization has NOT previously participated in any of the above initiatives	Navigate to the <u>Ambulatory Quality Improvement registration form</u> (www.heart.org/RegisterMyOutpatientOrg). Follow the instructions within the registration form to select the initiatives in which you would like to participate and complete the form with your Health Care Organization's details.
If your organization has previously registered for any of the above initiatives, and is submitting data for the <u>same</u> initiative(s)	No need to re-register . Users with an existing account can navigate directly to the data submission platform at https://aha.infosarioregistry.com/login and log in. They will be immediately redirected to the Community Page for their organization.
If your previously-registered organization wants to register for another initiative	Fully complete the <u>Ambulatory Quality Improvement registration form</u> and request access to that new initiative.
If you want to submit data for multiple individual sites through our CSV Uploader feature	Register your individual sites via the <u>Multi-Site registration form</u> -or- submit a request in our <u>Contact Us</u> form for help.
If your organization is registered, but you need a new user account	Submit a request in our <u>Contact Us</u> form, or contact the <u>Help Desk</u> . Please do not submit the registration form again to help us reduce duplicates.

Once registered, an account will be created in the data submission platform for new participants within 3 business days. Check your spam/junk filters for your log-in credentials. If you have no credentials after 3 business days, <u>contact us</u>.



Troubleshooting and Support

- **Forgot your username or password?** Please follow the "Forgot password?" instructions at the log-in landing page. For additional help, see the <u>troubleshooting</u> page.
 - We highly recommend setting up your Challenge Questions in your account these enable you to reset your password in most scenarios without contacting the Help Desk.
- Locked out of your account? Reach out to the platform Help Desk (InfosarioOutcomeSupport@Quintiles.com or 888-526-6700) or submit a Contact Us request. You can also reach out directly to your local AHA field staff member to submit a ticket on your behalf.

Navigating the Online Platform

NOTE: If the user has access to submit data for **more than one organization**, the user will be prompted to select one organization at a time for which they can make updates and submit data. After selecting the specific organization, the user will be directed to that organization's community page. To navigate to a different organization's page, click "Switch Current View". If you have access to submit data for multiple sites via the "Upload" feature, navigate to the profile labeled "(Health System Profile)".

Toggle between different HCO views

Currently Viewing Ambulatory Quality Registry Switch Current View DASHBOARD **a** Community Page PLATFORM Program Forms Form Management A Notifications ANALYTICS C Operational Reports RESOURCES Library ACCOUNT My Account 🖰 Log out

Ambulatory Quality Registry AQ Demo 1 ~ AQDEMO1 AQ Demo 2 ~ AQDEMO2 AQ Demo 3 ~ AQDEMO3 AQ Demo 4 ~ AQDEMO4 AQ Demo Facility 5 ~ AQDEMO5

Select a view



views AQ Demo 4- AQDEMO4 AQ Demo Facility 5 - AQDEMO5 The Health Care Organization (HCO) being viewed is located at the top of the panel. In this case, the view for "**AQ Demo Facility 5**" is open. "AQDEMO5" is the **Facility ID** – normally this will be a 6-digit number.

Switch Current View – (When applicable) Allows user to toggle between other organizations for which they have user permissions. Can view and submit data for multiple organizations.

Community Page - HCO home page. Quickly access frequently used sections.

Program Forms – Contains online forms for submitting data – <u>enter data in Program</u> <u>Forms</u> by the deadline to be eligible for an achievement award.

Form Management – Contains forms to add/edit site characteristics. Enter site-specific information here to pull advanced benchmarking reports.

Notifications - View updates on recognition, updates to the platform, and other news.

Operational Reports – View HCO and benchmarking data.

Library – Locate all resources related to the registry (e.g., data entry worksheets, user guides, measure information).

My Account - Manage your password and account security questions.



Entering Data – Adding Your Program Forms

STEP 1


Select **"Program Forms"** from the left navigation bar, or from the Community Page. Here you can enter and submit data into one or more forms to be eligible for recognition.

STEP 2

There are two sections on the "Program Forms" page.

- Add Forms | This section lists the initiatives to which your HCO has access.
 - \circ $\;$ Select ${\bf Add} \, {\bf New}$ to start a new data submission per initiative.
 - Missing a program form? Please submit the <u>registration form</u> for the new initiative. If you feel there is an error with your account, please <u>contact us</u>.
- Edit Forms | Section to edit existing data forms.
 - Select an existing form's link to edit data from prior years (2023 and earlier) or the current reporting year (2024).

NOTE: The form's year refers to the year data was collected (e.g., for 2025 achievement awards, an HCO will be submitting data collected during the 2024 calendar year on a form labeled 2024).





Review the existing forms (if any) under the **Edit Forms** section.

- Program forms containing "2024" will be used to determine award eligibility for 2025.
 - **To edit an existing form** for year 2023 or prior, click on the link (ex: "Target: BP 2023") and skip to STEP 1 below for the chosen initiative.
 - Why edit a prior year's form? Editing data in a 2023 form or earlier does not change your award status for that year, but it will update your HCO's operational reports and allow for more accurate year-over-year comparisons.
- **STEP 4**

To add a new 2024 program form, under the **Add Forms** section, click "Add New" to the right of the desired initiative.

- Enter the Reporting Year (2024) and click "Submit." The Reporting Year refers to the year the data were collected.
- If selecting the year using the calendar icon, select any month and day within the Reporting Year.

Entering Data – Target: BP™

NOTE: It is highly recommended that users first gather data using the Target: BP™ <u>Data Collection</u> <u>Worksheet</u>. Organizations should report on data collected only from January 1 to December 31, 2024. The deadline to submit data is Friday, May 16, 2025, at 11:59 PM ET. When finished with all entry, check the "Data Entry Complete" checkbox, and hit "Save and Exit". NOTE: Data can still be revised before the submission deadline.

Organizations must submit complete 2024 data under ALL tabs to be eligible for 2025 awards.

				Save	Save & Exit 🔳 Tabs x
			Course of the set to service of		Facility Information (Tab 1 of 3)
Facility In	formation (Tab 1 of 3)		Save often to prevent losing your work.		M, A, P Activities (Tab 2 of 3)
		24			SMBP, EHO Activities (Tab 3 of 3)
completion of Target: BP Da	try is complete on ALL TABS (located in the righthand "Tabs" panel), ple if data submission - there is no formal "Submit" button. Data Entry Complete	ሰጥ ease check the	e "Data Entry Complete" box and click the Save (& Exit button above. This constit	utes
Enter data ir View all You can Enter data o	for Data Submission: all fields on all tabs, located in the righthand panel. tabs by clicking the blue icon with 4 lines in the top right of the window. also navigate using the "Next" and/or "Previous" buttons a fine bottom of eac nyour total patient population ages 18 and older in Quarking and use ar organization's evidence-based blood pressure men thement activities in the When finished, check the 'Data Entry Complete' box and hit Save and Exit.	e this same tota			Complete ALL Tabs. Attest to your organization's completion of evidence- based BP activities on Tab 2 and Tab 3.
All question Leave no fie The <u>auto-su</u>	Data can still be revised before the submission deadline.	st match the	ou don't know, select "Not sure". <u>total adult (ages 18 and older) patient population</u> I must match the <u>total adult (ages 18 and older) pa</u>		on 3 (Q3).
Q4 and Q5 align with the denominator and numerator of the <u>Controlling High Blood Pressure measure (MIPS#236)</u> . This measure is widely implemented in various Center for Medicaid and Medicare Services (CMS) and private payor reporting programs. You can also use NQF 0018 measure logic. While they may differ slightly, the use of either measure specification is acceptable.					
Percentage of	cription: <u>Controlling High Blood Pressure measure (MIPS#236)</u> . patients 18-85 years of age who had a diagnosis of essential hypertension st lood pressure was adequately controlled (<140/90 mmHg) during the measu				d, and whose
	OR: Patients 18-85 years of age who had a 2024 visit (in-office or telehealth en as of the measurement period. Please see notes underneath Q4 for addition			ore and continuing into, or starting	during the

TIP: Save data often by clicking on the Save button in the top right of the page.

STEP 1

Respond "yes" or "no" to Questions 1 and 2 (Q1 and Q2). Q1 asks if your organization directly treats patients with hypertension. Q2 asks if you certify that your attestations are accurate. A "yes" response on both is required to be eligible for an award.

Q1. Does your organization diagnose and manage adult patients with hypertension, including prescribing and managing medications?	○ Yes ○ No
Q2. I am a designated representative of my organization and certify that the following attestations are accurate to the best of my knowledge:	○ Yes ○ No

STEP 2

Enter your HCO's data into questions 3 – 7 (Q3 – Q7). For Q4 and Q5, use Denominator and Numerator data from <u>MIPS #236: Controlling High Blood Pressure</u>. Question 6 asks if your data included blood pressure readings from patients' remote monitoring devices – please answer to the best of your knowledge.

patients ages 66 or older by the end of the measurement period who are living long term in a nursing home any time on or before the e with an indication of frailty during the measurement period who also meet any of the following advanced illness criteria: advanced illne	your HCO's data and Q5 based on S #236 criteria.
NUMERATOR Q5. Using MIPS #236 criteria, of the patients qualifying for the denominator (Question 4), what is the number of patients whose BP from their most recent 2024 visit is adequately controlled (systolic BP >0 mmHg and <140 mmHg, and diastolic BP >0 mmHg and <90 mmHg)?	
Q5. Note: If there are multiple blood pressures on the same date of service, use the lowest systolic and lowest diastolic blood pressure. See additional gu Q6. Did your numerator data include digitally transmitted blood pressure readings from a patient's remote monitoring device? O Yes O No O Not Sure (Note: Your response will not affect your recognition status.) Q7. How many providers are there for the Healthcare Organization? Include all	Please indicate if, to the best of your knowledge, home BP readings were used to determine patients with controlled BP.

Depending on your answers to Q4 and Q5, you may also be required to answer Q4a and/or Q5a.

Question 4a will only appear if your answer to Q4 (the denominator) is less than or equal to 10. If it is, you are required to provide context as to why your denominator is small, and, if applicable, why your overall patient population may be small.

Q4a. REQUIRED – Please provide context on why your organization has ≤10 adult patients meeting the denominator criteria and, if applicable, why your overall patient population may be small. Examples may include unique characteristics of your patient demographics or location.(500-character limit).	
---	--

Question 5a will only appear if your performance on the measure (numerator divided by denominator) is 90% or greater. If it is, you are required to verify that the data is accurate and share details that may be contributing to an above average performance.

Q5a. REQUIRED – Your control rate on the measure is above 90% control. Please <i>v</i> erify your data, and if accurate, provide details that may be contributing to your	
above average performance. (500-character limit).	



For Q8, enter your HCO's data regarding the race and ethnicity of your patient population. Each field must have a data value entered. Even if it is a zero, type "0." Blanks will generate an error. See Table 3B of the <u>HRSA Uniform Data System Reporting</u> <u>Requirements for 2024 Health Center Data</u> for more information.

All fields must contain a value. Please enter "0" where there are no patients.	g race and ethnicity (based on Table 3B of the <u>HRSA Uniform Data System Reporting Requirements for 2024 Health Center Data</u>):
Asian - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Asian - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Native Hawaiian - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Native Hawaiian - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Other Pacific Islander - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Other Pacific Islander - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Black/African American - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Black/African American - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
American Indian or Alaska Native - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
American Indian or Alaska Native – Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
White - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
White - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
More than one race - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
More than one race Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Unreported/Unknown Race – Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Race Known (Any), but Hispanic, Latino/a, or Spanish Origin Unreported/Unknown: Total Patient Count		
Both Race and Hispanic, Latino/a, or Spanish Origin Unreported/Unknown: Total Patient Count		
Race/Ethnicity Summation: Total Patient Count (MUST EQUAL YOUR RESPONSE TO QUESTION 3)		

STEP 4

For Q9 enter your HCO's data regarding your patient population's primary payor groups. Each field must have a data value entered. Even if it is zero, type "0". Blanks will generate an error. See the last page of the <u>Data Collection Worksheet</u> for details on how to assign a payor group to each patient.

Q9. How many of your total adult patient population (ages 18 and older) are primarily attributed to t All fields must contain a value. Please enter "0" where there are no patients. Medicare: Total Patient Count	he following payor groups:
Medicare: Total Patient Count	
Medicaid: Total Patient Count	
Private Health Insurance: Total Patient Count	
Other Public: Total Patient Count	
Uninsured / Self-Pay: Total Patient Count	
Other / Unknown: Total Patient Count	
Payor Group Summation: Total Patient Count (MUST EQUAL YOUR RESPONSE TO QUESTION 3)	

STEP 5

Under **Tabs** on the righthand side, or using the **Next** button at the bottom of the screen, navigate to the 2nd tab, **"M, A, P Activities."** Select responses for the "Measure Accurately" pillar questions 10a, 10b, and 12 – 15 (Q10a, Q10b, Q12 – Q15). For question 11 (Q11), select the percentage of your organization's devices that are validated. Completing all questions is required for award eligibility.

			Save	Save & Exit	Tabs x
					Facility Information (Tab 1 of 3)
M, A, P Activities (Tab 2 of 3)					M, A, P Activities (Tab 2 of 3)
Evidence-Based BP Activities The American Heart Association and American Medical Association aims to support re <u>Practice Guideline</u> recommendations. Please see guidance in the <u>Data Collection Worksheet</u> and on the <u>Evidence-Based Act</u> tab. These include Measure Accurately, Act Rapidly, Partner with Patients. Self Measure and clinical practice within your organization should answer or be consulted on these	- <u>tivities webpage</u> for further details and ired Blood Pressure, and Equitable He	Navigate to the " M , (Tab 2 of 3)" and r the questi	espond to all	nd the next	SMBP, EHO Activities (Tab 3 of 3)
Measure Accurately Please answer the questions below to describe your organization's practices during 2 recognition.	2024. Your response will help us gauge	adoption of best practices and evalua	te your eligibility for additio	nal	
BP Device Calibration & Validation I attest that my organization: Q10a. Calibrates ALL aneroid devices per the 2019 AHA Scientific Statement: Measurement of BP in Humans (every 2–4 weeks for handheld devices and every 6 months for wall-mounted devices). Resources: 2019 AHA Scientific Statement: Measurement of BP in Humans	○ Yes ○ No ○ No aneroid devices	s O Not sure	Answer each s	single-sele	ect question.
Q10b. Calibrates ALL oscillometric devices per the 2019 AHA Scientific Statement: Measurement of BP in Humans (Nearly all manufacturers recommend that	○ Yes ○ No ○ No oscillometric de	evices O Not sure			

For question 11 (Q11), select the percentage of your organization's devices that are validated from the drop-down menu. If you do not know the percentage, select "Not sure."


Q11. Please review the devices listed on ValidateBP.org or similar international sources. Report the percentage of your organization's oscillometric devices (semi- or fully-automated) that are validated* for clinical accuracy. Approximate percentages are acceptable.	Not sure	~
PLEASE NOTE: If you have no oscillometric devices, select 0%.	0%	
*Validated = device is listed on US Blood Pressure Validated Device Listing (VDL [™]) acce	1-10%	vice listings.
	11-20%	
BP Measurement Knowledge & Skills	21-30%	
l attest that my organization:	31-40%	
Q12. Strengthens BP measurement knowledge every 6-12 months for all staff	41-50%	
who measure blood pressure or train staff to measure blood pressure (using	51-60%	
Achieving Accuracy BP Measurement e-learning module OR CME/CE Course: The	61-70%	
Importance of Measuring Blood Pressure Accurately (free webinar), OR another	71-80%	
structured curriculum).	81-90%	
Resources: <u>Achieving Accuracy BP Measurement e-learning module</u> OR <u>CME/CE Course</u>	91-100%	<u>curately</u>

Continue through answering the "Act Rapidly" pillar questions (Q16-Q21) and "Partner with Patient" pillar questions (Q22-Q27). Each of these questions has an option for "Yes," "No," or "Not sure."

STEP 6

Under **Tabs** on the righthand side or using the **Next** button at the bottom of the screen, navigate to the 3rd tab, **"SMBP, EHO Activities."**

Select responses for the "Self-Measured Blood Pressure" pillar questions (Q28-Q33) and "Partner with Patient" pillar questions (Q34-Q39). Each of these questions has an option for "Yes," "No," or "Not sure."



STEP 7 Share which quality improvement (QI) activities for blood pressure management your health care organization engaged in during the last year. Select all that apply.

Quality Improvement Activities				
The American Heart Association and American Medical Association want to learn more about your efforts to improve quality of health care delivery in your organization during the last year. This information helps us understand trends in health care quality improvement and design programs that meet our participants' needs. Please review the following questions and choose any that may apply.				
Q40. Which quality improvement (Q!) activities for blood pressure management has your health care organization engaged in during the last year? (Select all that apply)	TargetBP.org Self-Guided QI Resources (Ex. Quick Start Guides, Webinars) Hypertension activities with a local AHA representative AHA National QI collaborative (Ex. Hypertension Control Accelerator) AMA MAP(TM) Hypertension Client National-level learning programs or collaboratives (Ex. CDC Million Hearts, NACHC, NHCI)			
If you select "Other(s)" - include details in a text entry field below.	State or Regional Level Learning Collaboratives (Ex. Delaware Hypertension Control Network, CardlOH in Ohio) Third-party QI consulting services (Ex. Quality Improvement Organization (QIO)) Internal QI activities (led by your own organization) None / I am not sure			
	Other(s) – Include details below (optional)			

STEP 8

When all data are entered, navigate to the **"Facility Information"** tab, check the **"Data Entry Complete"** checkbox and click the **Save & Exit** button at the top of the page.


Data may be edited at any time. All achievement awards will be based on a "snapshot" of data available in the platform on May 16, 2025, at 11:59 PM ET.



Entering Data – Check. Change. Control. Cholesterol™

NOTE: It is highly recommended that users first gather data using the Check. Change. Control. Cholesterol[™] <u>Data Collection Worksheet</u>. Organizations should report on data collected only from January 1 to December 31, 2025. The deadline to submit data is **Friday, May 16, 2025, at 11:59 PM ET**. When finished with all entry, check the "**Data Entry Complete**" checkbox, and hit "**Save and Exit**." NOTE: Data can still be revised before the submission deadline.

Organizations must submit complete 2024 data under ALL tabs to be eligible for 2025 awards.



TIP: Save data often by clicking the Save button in the top right of the page.

STEP 1

Respond "yes" or "no" to Questions 1 and 2 (Q1 and Q2). Q1 asks if your organization directly treats patients with high cholesterol. Q2 asks if you certify that your attestations are accurate. A "yes" response on both is required to be eligible for an award.

Participant Organizational Information	
Q1. Does your organization diagnose and manage adult patients with high cholesterol, including prescribing and managing medications?	○Yes ○No
Q2. I am a designated representative of my organization and certify that the following attestations are accurate to the best of my knowledge.	○ Yes ○ No



Enter your HCO's data into questions 3 - 4 (Q3 - Q4).

Q3. What is the total number of patients 18 years of age and older in the Health are Organization, regardless of diagnosis? Patients must have had at least one 2024 visit (in-office or telehealth encounter). Exclude acute care visits.

(Note: In subsequent questions, you will be asked to break down this total by primary payor and race/ethnicity. These questions are now the same in Target: BP and Target: Type 2 Diabetes to reduce data burden, if you are participating. The measure numerators/denominators for each program utilize different age ranges per national measure specifications.)

Q4. How many providers are in your Healthcare Organization? Include physicians and mid-level providers.

STEP

STEP 2

For Q5, enter your HCO's data regarding the race and ethnicity of your patient population. Each field must have a data value entered. Even if it is a zero, type "0." Blanks will generate an error. See Table 3B of the <u>HRSA Uniform Data System Reporting</u> <u>Requirements for 2024 Health Center Data</u> for more information.

Q5. How many of your total adult patient population (ages 18 and older) self-identify as the following race and ethnicity (based on Table 3B of the HRSA Uniform Data System Reporting Requirements for 2024 Health Center Data): All fields must contain a value. Please enter "0" where there are no patients.				
Asian - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Asian - Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Native Hawaiian - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Native Hawaiian - Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Other Pacific Islander - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Other Pacific Islander - Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Black/African American - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Black/African American - Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
American Indian or Alaska Native - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
American Indian or Alaska Native – Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
White - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
White - Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
More than one race - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
More than one race Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Unreported/Unknown Race – Hispanic, Latino/a, or Spanish Origin: Total Patient Count				
Race Known (Any), but Hispanic, Latino/a, or Spanish Origin Unreported/Unknown: Total Patient Count				
Both Race and Hispanic, Latino/a, or Spanish Origin Unreported/Unknown: Total Patient Count				
Race/Ethnicity Summation: Total Patient Count (MUST EQUAL YOUR RESPONSE TO QUESTION 3)				



For Q6, enter your HCO's data regarding your patient population's primary payor groups. Each field must have a data value entered. Even if it is zero, type "0". Blanks will generate an error. See the last page of the <u>Data Collection Worksheet</u> for details on how to assign a payor group to each patient.

Q6. How many of your total adult patients 18 years of age and older are primarily attri All fields must contain a value. Please enter "0" where there are no patients. Medicare: Total Patient Count	buted to the following payor groups:
Medicaid: Total Patient Count	
Private Health Insurance: Total Patient Count	
Other Public: Total Patient Count	
Uninsured / Self-Pay: Total Patient Count	
Other / Unknown: Total Patient Count	
Payor Group Summation: Total Patient Count (MUST EQUAL YOUR RESPONSE TO QUESTION 3)	


STEP 5

For Q7 and Q8, enter your HCO's data regarding its calculation and documentation of ASCVD Risk using the Pooled Cohort Equations CV Risk Calculator. Selecting "Yes" on either question will prompt additional required questions.

Q7. Does your organization or its individual clinical providers consistently calculate ASCVD Risk (utilizing the Pooled Cohort Equations CV Risk Calculator)?	● Yes ○ No
Resource: 2018 ACC/AHA ASCVD Pooled Cohort Equations CV Ris	sk Calculator
If Yes, where?	\bigcirc My organization currently calculates ASCVD Risk Estimations in our EHR.
Selecting "Yes" in Q7 will prompt additional required questions.	 My organization relies on clinicians to calculate ASCVD Risk Estimation external to our EHR (our EHR does not have this functionality). Please select where your organization or its individual providers currently calculates ASCVD Risk.
Q8. Does your organization or its individual clinical providers document the ASCVD Risk Score (calculated utilizing the Pooled Cohort Equations CV Risk Calculator)?	● Yes ○ No
Resource: 2018 ACC/AHA ASCVD Pooled Cohort Equations CV Risk Calculator	
If Yes, where?	O My organization currently collects the results of ASCVD Risk Estimations in a discrete field in our EHR.
Selecting "Yes" in Q8 will prompt additional required questions.	 My organization currently collects the results of ASCVD Risk Estimations in a notes field or other non-discrete field in our EHR (there is not a dedicated space in our EHR to capture this information). Please select where your organization or its individual providers documents the ASCVD Risk Score.
	documents the ASCVD Risk Score.



For Q9, indicate if your HCO organization operationalizes a specific treatment plan for managing patients considered very high-risk for future ASCVD events. Selecting "Yes" will prompt additional required elements, of which multiple selections can be chosen.



STEP 7

For Q10, indicate if your HCO is committed to continuously improving use and data capture of ASCVD Risk Estimations. You must select "Yes" to be eligible for an achievement award.

Q10. My organization is committed to continuously improving use and data O Yes O No capture of ASCVD Risk Estimations into our workflows and EHR systems.

STEP 8

For Q11, describe your organization's familiarity and use of the <u>Predicting Risk of</u> <u>cardiovascular disease EVENTs (PREVENT™) calculator.</u>

Q11. The American Heart Association launched a new tool in November 2023 to predict a person's long-term risk of cardiovascular disease. The Predicting Risk of cardiovascular disease EVENTs (PREVENT[™]) calculator aims to help clinicians implement risk assessment for cardiovascular disease and facilitate clinician-patient discussion to optimize prevention for cardiovascular disease, including ASCVD and heart failure. This tool factors in kidney disease and metabolic disease, including Type 2 diabetes and obesity, as well as indicators of social deprivation. Please describe your organization's familiarity and use of the PREVENT calculator:

O My organization currently utilizes the PREVENT calculator and automatically collects the results and calculates the risk scores in a discrete field in our EHR.


- My organization currently utilizes the PREVENT calculator and requires the clinicians to manually insert data for risk score calculations.
- Some clinicians to manually insert data for risk score calculations
 Some clinicians in my organization use the PREVENT tool as a
- standalone tool, but it is not integrated into the EHR.
- O The clinicians at my organization are familiar with the PREVENT
- calculator but have not yet utilized the tool.
- \bigcirc My organization is currently unfamiliar with the PREVENT calculator.
- \bigcirc I am not sure what my organization's familiarity or use of the PREVENT calculator is.

Resource:

Predicting Risk of cardiovascular disease EVENTs (PREVENT™) calculator Development and Validation of the American Heart Association's PREVENT Equations



For Q12, share which quality improvement (QI) activities for high cholesterol and/or ASCVD management has your health care organization engaged in during the last year. Select all that apply.



STEP 10

Under **Tabs** on the righthand side, or using the Next button at the bottom of the screen, navigate to the "Measure Submission" tab. For Q10 and Q11, enter Denominator and Numerator data for MIPS #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. Patients should be specific to the 2024 calendar year and reflect all who meet one or more of the three denominator criteria. Please refer to the Data Collection Worksheet for details.

		Save Save & Exit	Tabs X	
To be eligible to receive a Check. Change. Control. Cholesterol Award, organizations will er Treatment of Cardiovascular Disease in questions 13 and 14. respectively. Both "Participa	Save often.	e #438: Statin Therapy for the Prevention and eted for award eligibility.	Participant Information	
Measure Description: MIPS Measure #438: Statin Therapy for the Prevention and Treat (Measurement period = January 1 – December 31, 2024)	tment of Cardiovascular Disease			
Denominator**: All patients who had a visit (in-office or qualifying telehealth encounter) du be careful not to count them twice – determine patient eligibility in order of each criterion. So				
 ALL patients, regardless of age, who were previously diagnosed with or currently have a di OR Patients aged 20 to 75 years who have ever had a laboratory result of low-density lipoprot familial hypercholesterolemia; OR Patients aged 40 to 75 years at the beginning of the performance period with Type 1 or Typ OR Patients aged 40 to 75 years at the beginning of the performance period with a 10-year AS 	tein cholesterol (LDL-C) ≥ 190 mg/dL or were previously diag	nosed with or currently he Navigat Measure S ta	ubmission	
$\star\star All$ patients who meet one or more of the above criteria would be considered at high risk f	for cardiovascular events under the ACC/AHA guidelines.			
EXCLUSIONS (always remove from denominator): Patients who are breastfeeding, or who	o have a rhabdomyolysis diagnosis active any time during 20	024.		
EXCEPTIONS (remove from denominator if patient meets one of these criteria AND is NOT taking a statin): Patients with statin-associated muscle symptoms or an allergy to statin medication; Patients with active liver or hepatic disease or insufficiency: Patients with end stage renal disease; Patients receiving palliative or hospice care; patients with documentation of a medical reason for not being prescribed statin therapy.				
Numerator: Patients who are actively using or who receive an order (prescription) for statin	therapy at any point during the measurement period.			
Denominator: Q13. identify the number of patients in EACH of the above four risk groups. What is the sum of patients in all four risk groups? Avoid double-counting patients who fail into more than one risk group. NOTE: All four risk groups must be factored into the final denominator total. You must use the MIPS #438 measure criteria as specified – using a different measure, using eligibility	for Q13 on MI	your HCO's data 3 and Q14 based PS #438 criteria.		
Numerator: Q14. Using MIPS #438 criteria, of the patients given in Question 13, how many were prescribed or were actively using statins at any point during 2024?	· · · · · · · · · · · · · · · · · · ·			



NOTE: Depending on your answers to Q3, Q13, and Q14, you may also be required to answer Q13a, Q14, and/or Q15 and either Q16 or Q17. These conditional questions will be walked through below.

Question 13a will only appear if your answer to Q13 (the denominator) is less than or equal to 10. If it is, you are required to provide context as to why your denominator is small, and, if applicable, why your overall patient population may be small.

Q13a. REQUIRED – Please provide context on why your organization has ≤10 adult patients meeting the denominator criteria and, if applicable, why your overall patient population may be small. Examples may include unique characteristics of	
your patient demographics or location." (500-character limit).	

Question 14a will only appear if your performance on the measure (numerator divided by denominator) is 90% or greater. If it is, you are required to verify that the data is accurate and share details that may be contributing to an above average performance.

Q14a. REQUIRED – Your control rate on the measure is above 90% control. Please verify your data, and if accurate, provide details that may be contributing to your above average performance. (500-character limit).	

Question 15 will only appear if the Denominator (total patients in measure risk groups) is less than 6% of your total patient population given in Q3 (ex: 5 patients out of 100 total patients).

Denominator: Q13. Identify the number of patients in EACH of the above four risk groups. What is the sum of patients in all four risk groups? Avoid double-counting patients who fall into more than one risk group. NOTE: All four risk groups must be factored into the final denominator total.	200 If the Denominator value is <6% of your
You must use the MIPS #438 measure criteria as specified – using a different measure eligibility Numerator:	total a coulation (citizen in O2) countil
Q14. Using MIPS #438 criteria, of the patients given in Question 13, how many were prescribed or were actively using statins at any point during 2024?	100
Q15. Was the denominator (Q13 above) determined based on a subset or sample of patients in your organization?	 Yes. Record sampling, or a specific subset of patients was used to determine measure compliance. No. The denominator includes all patients in our total patient population who meet the MIPS #438 measure criteria as specified for CMS use.

If Q15 appears, and you select "Yes": You will be prompted to briefly describe your sampling method (including initial population sampled, sample size, and selection methods) and reason for sampling. This description is <u>required</u> to be eligible for an award.

Q15. Was the denominator (Q13 above) determined based on a subset or sample of patients in your organization?	• Yes. Record sampling, or a specific subset of patients was used to determine measure compliance.
	\odot No. The denominator includes all patients in our total patient population who meet the MIPS #438 measure criteria as specified for CMS use.
Q16. REQUIRED - Please describe your sampling method (including initial population sampled, sample size, and selection methods) and reason for sampling. (500-character limit)	



If Q15 appears, and you select "No": You will be notified that the number of patients across all risk groups are considered low compared to your overall population. Please describe any unique characteristics of your patients or organization for consideration. This description is <u>required</u> to be eligible for an award.

Q15. Was the denominator (Q13 above) determined based on a subset or sample of patients in your organization?	 Yes. Record sampling, or a specific subset of patients was used to determine measure compliance. No. The denominator includes all patients in our total patient population who meet the MIPS #438 measure criteria as specified for CMS use.
Q17. REQUIRED - The denominator entered in Q13 may be considered small compared to your overall population in Q3. Please ensure your denominator includes ALL patients in ALL four risk groups, and all other measure logic is appropriately applied. If the measure has been appropriately applied, please describe any unique characteristics of your patients or organization for consideration that might contribute to having a small number of patients at risk for ASCVD. (500-character limit)	

STEP 11

When all data are entered, check the **"Data Entry Complete"** checkbox and click the **Save & Exit** button at the top of the Participant Information page. Data may be edited at any time. All achievement awards will be based on a "snapshot" of data available in the platform on May 16, 2025, at 11:59 p.m. ET.



Entering Data – Target: Type 2 DiabetesSM

NOTE: It is highly recommended that users first gather data using the Target: Type 2 DiabetesSM <u>Data</u> <u>Submission Worksheet</u>. Organizations should report on data collected only from January 1 to December 31, 2024. The deadline to submit data is **Friday, May 16, 2025, at 11:59 PM ET**. When finished with all entry, check the **"Data Entry Complete"** checkbox, and hit **"Save and Exit"**.

NOTE: Data can still be revised before the submission deadline.

Organizations must submit complete 2024 data under ALL tabs to be eligible for 2025 awards (questions 1-16, and either Option 1 or Option 2 for questions 17-20 on the Measure Submission tab).

TIP: Save data often by clicking on the Save button in the top right of the page.

	Save		Tabs	x
		2	Participant Information	
Participant Information			Clinical Practices	
Reporting Year 2024	Save often.		Measure Submission	
Once data entry is complete on ALL TABS (located in the righthand "Tabbis" panel), please check the "Data Entry Complete" box and click the Save & Exit button above. This constitutes completion of data submission - there is no formal "Submit button. Data Entry Complete				
Target: Type 2 Diabetes Data Submission				
Instructions for Data Submission The Target: Type 2 Diabetes program aims to reduce cardiovascular events and strokes in people living with	type 2 diabetes.		nto ALL tabs	
Recognition data entry requie When finished, check the 'Data Entry	ward eligibility.	for award	eligibility.	
The Participant Information	ormation on current clinical practices for caring for patients with diabetes.			
In the Measure Submission t Data can still be revised before the	elect measures of patients seen in the 2024 calendar year.			
Tabs are located in the right submission deadline.	of the data submission window. You can also navigate using the "Next" and/o	or "Previous"		
Additional resources for submission are located in the Library, which you can find in the lefthand navigation bar.				
Participant Organizational Information				_

STEP 1

Respond "yes" or "no" to Questions 1 and 2 (Q1 and Q2). Q1 asks if your organization directly treats patients with diabetes. Q2 asks if you certify that your attestations are accurate. A "yes" response on both is required to be eligible for an award.

Q1. Does your organization diagnose and manage adult patients with diabetes, including prescribing and managing medications?	○ Yes ○ No
Q2. I am a designated representative of my organization and certify that the following attestations are accurate to the best of my knowledge.	○ Yes ○ No



Enter your HCO's data into questions 3 and 4 (Q3 and Q4).

Q3. What is the total number of patients 18 years of age and older in the Healthcare Organization, regardless of diagnosis? Patients must have had at least one 2024 visit (in-office or telehealth encounter). Exclude acute care visits.	
(Note: In subsequent questions, you will be asked to break down this total by pr Control. Cholesterol to reduce data burden, if you are participating. The measure numerators/denominators for each program utilize different age	imary payor and race/ethnicity. These questions are now the same in Target: BP and Check. Change. ranges per national measure specifications.)
Q4. How many providers are in your Healthcare Organization? Include physicians and mid-level providers.	

STEP 3

STEP 2

For Q5, enter your HCO's data regarding the race and ethnicity of your patient population. Each field must have a data value entered. Even if it is a zero, type "0." Blanks will generate an error. See Table 3B of the <u>HRSA Uniform Data System Reporting</u> Requirements for 2024 Health Center Data for more information.

Q5. How many of your total adult patient population (ages 18 and older) self-identify as the following All fields must contain a value. Please enter "0" where there are no patients.	g race and ethnicity (based on Table 3B of the <u>HRSA Uniform Data System Reporting Requirements for 2024 Health Center Data</u>	<u>)):</u>
Asian - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Asian - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Native Hawaiian - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Native Hawaiian - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Other Pacific Islander - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Other Pacific Islander - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Black/African American - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Black/African American - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
American Indian or Alaska Native - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
American Indian or Alaska Native – Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
White - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
White - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
More than one race - Non-Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
More than one race Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Unreported/Unknown Race - Hispanic, Latino/a, or Spanish Origin: Total Patient Count		
Race Known (Any), but Ethnicity Unreported/Unknown: Total Patient Count		
Both Race and Ethnicity Unreported/Unknown: Total Patient Count		
Race/Ethnicity Summation: Total Patient Count (MUST EQUAL YOUR RESPONSE TO QUESTION 3)		



For Q6, enter your HCO's data regarding your patient population's primary payor groups. Each field must have a data value entered. Even if it is zero, type "0". Blanks will generate an error. See the last page of the <u>Data Submission Worksheet</u> for details on how to assign a payor group to each patient.

Q6. How many of your total adult patients 18 years of age and older are p All fields must contain a value. Please enter "0" where there are no p	
Medicare: Total Patient Count	
Medicaid: Total Patient Count	
Private Health Insurance: Total Patient Count	
Other Public: Total Patient Count	
Uninsured / Self-Pay: Total Patient Count	
Other / Unknown: Total Patient Count	
Payor Group Summation: Total Patient Count (MUST EQUAL YOUR RESPONSE TO QUESTION 3)	

STEP 5

Under **Tabs** on the righthand side, or using the Next button at the bottom of the screen, navigate to the 2nd tab, "**Clinical Practices.**" Select responses for questions 7 – 14. Completing all questions is required for award eligibility.

		Save	Save & Exit	I	Tabs	x
				2	Participant Information	
Clinical Practices	Save often				Clinical Practices	
Guidance for Questions 7-12 Questions 7-12 are meant to serve as an assessment of your organization's practices for diabetes care, particularly a (CVD), use of guideline-based medical therapies, and preventing chronic kidney disease (CKD). If you are unable to a familiar with these areas. You must respond to each question to be eligible for an award, but your responses do not affect your award status. improvement and inform future educational resources for program participants.	issessing and managing r nswer a particular questi	isk for cardiovascula	ate to the	аb.	Measure Submission	
For FAQs and additional resources, please visit the "Related Resources" section at <u>https://www.heart.org/en/profess</u> <u>diabetes/outpatient-learn-more-and-register.</u>	ional/quality-improvemer	<u>tt/target-type-2-</u>				
Please consider the organizational area your data submission represents. For example, if the facility name in the other data submitted are specific to this facility, please answer the below questions with only North Clinic in mind. However,						



For Q7 and Q8, you can select multiple options as they apply to your organization's protocols and treatment plans.

Q7. Which of the following key characteristics do your clinical teams address for patients with type 2 diabetes as part of organizational standard protocols? (Select all that apply)	Current lifestyle Co-morbidities i.e. ASCVD, HF, CKD Co-morbidities i.e. ASCVD, HF, CKD Clinical characteristics associated with increased CVD risk i.e. age, blood pressure, cholesterol, smoking, age, weight, etc. Issues such as motivation and depression Social determinants of health (economic and social conditions that may affect a patient's health) Other characteristics not listed We don't have a standard protocol to address key characteristics of patients with type 2 diabetes. I don't know / I'm not sure
Q8. When your organization operationalizes treatment plans for managing patients with type 2 diabetes, which of the following considerations does the treatment plan include as standard process? (Select all that apply)	 Comprehensive lifestyle modification recommendations Diabetes self-management education and support Use of guideline-based treatment algorithms (such as the ADA Standards of Care treatment algorithm or ACC/AHA treatment of T2DM for primary prevention of CVD algorithm) by providers and care teams Use of Pooled Cohort Equations CV Risk Calculator for CVD risk-based treatment decisions related to hypertension and lipid management in patients with type 2 diabetes Use of AHA Predicting Risk of cardiovascular disease EVENTs (PREVENT(TM)) calculator for primary prevention patients (without ASCVD or HF) to assess 10- or 30-year CVD risk. Use of guideline-based pharmacologic therapy inclusive of cardio protective antihyperglycemic agents, such as SGLT-2 inhibitors and GLP-1 receptor agonists We don't operationalize a specific treatment plan for patients with type 2 diabetes. None of the above I don't know / I'm not sure

STEP 7

For Q9, describe your organization's familiarity and use of the <u>Predicting Risk of</u> cardiovascular disease EVENTs (PREVENT[™]) calculator..

Q9. The American Heart Association launched a new tool in November 2023 to predict a person's long-term risk of cardiovascular disease. The Predicting Risk of cardiovascular disease EVENTs (PREVENT™) calculator aims to help clinicians implement risk assessment for cardiovascular disease and facilitate clinicianpatient discussion to optimize prevention for cardiovascular disease, including ASCVD and heart failure. This tool factors in kidney disease and metabolic disease, including Type 2 diabetes and obesity. Please describe your organization's familiarity and use of the PREVENT calculator: \bigcirc My organization currently utilizes the PREVENT calculator and collects the results in a discrete field in our EHR.

 \bigcirc My organization currently utilizes the PREVENT calculator and collects the results in a notes field or other non-discrete field in our EHR (there is not a dedicated space in our EHR to capture this information).

○ The clinicians at my organization are familiar with the PREVENT calculator and some, but not all, have begun to utilize the tool in their practice.

 \bigcirc The clinicians at my organization are familiar with the PREVENT calculator but have not yet utilized the tool.

 \bigcirc My organization is currently unfamiliar with the PREVENT calculator.

 \odot I am not sure what my organization's familiarity or use of the PREVENT calculator is.



Q10 and Q11 center on guideline-based pharmacologic therapies. Q10A-Q10F ask about which therapies are typically being prescribed and where they are prescribed.

	ation, angiotensin system blockers (ACE pically prescribed for patients with type 2 diabetes in: (Select all that apply)	 Another specialt Specialty clinic(s None of the about 	
Q10b. Within my organizati such as beta-blockers or diu blockers mentioned in (patients with	on, other antihypertensive medications Q10a-Q10f all have t available multi-selec	the same	or internal medicine or specialties (example: general cardiology, endocrinology, etc.) such as those focused solely on lipid or cardiometabolic care e – we refer to external specialty providers e – my organization neither prescribes these therapies nor has l
statins or non-statin alternativ	tion, lipid-lowering therapies, including /es, are typically prescribed for patients type 2 diabetes in: (Select all that apply)	Family medicine Another specialt Specialty clinic(s	or internal medicine by or specialties (example: general cardiology, endocrinology, etc.)), such as those focused solely on lipid or cardiometabolic care

Q11 asks about the prescribing barriers your organization faces. Multiple answers can be selected, scroll down to see all options. If you select the first option "System-based barriers such as formulary or prior authorization limitations" an additional question will appear that must be answered.

Q11. What barriers does your organization experience related to initiation of guideline-directed medical therapy for cardio protective antihyperglycemic agents, such as SGLT-2 inhibitors and GLP-1	System-based barriers such as formulary or prior authorization limitations [NOTE: Selecting th ⁻ option will prompt an additional question]
receptor agonists, for patients with type 2 diabetes? (Select all that apply)	 Limited clinic an awareness of the guideline-directed medical therapies or their application Clinic as unsure who is the primary lead in prescribing cardio protective antibyperglycemic agents, i.e., whether to refer to specialty provider for
If "System-based barriers" is selected, please select the factors that impact accessibility of cardio protective antihyperglycemic agents: (Select all that apply)	 Medications not on formulary Limited resources to assist with prior authorization Other factors
	Please select factors impacting accessibility of cardio/cardiorenal protective medications.



For Q12, you will be asked if you routinely evaluate kidney health for patients with type 2 diabetes. If you select yes, an additional required question will appear.

● Yes ○ No ○ I'm not sure

per patient

Q12. Does your organization routinely evaluate kidney health for patients with type 2 diabetes? (Select one option)

If "Yes" is selected, please select your processes for evaluating kidn by health for patients with diabetes: (Select all that apply)

Selecting "Yes" in Q12 will prompt additional required questions.

Assessment of estimated glomerular filtration rate (eGFR) less frequently than once per year per patient (such as once every 2 years)
 Assessment of urine albumin-creatinine ratio (uACR) at least once per year, per patient
 Assessment of urine albumin-creatinine ratio (uACR) less frequently than once per year per patient (such as once every 2 years)
 Assessment of kidney health using some other metric
 We do not have a process to evaluate kidney health in patients with diabetes.
 I don't know / I'm not sure

Assessment of estimated glomerular filtration rate (eGFR) at least once per year,

Please select factors impacting accessibility of cardio/cardiorenal protective medications.

○ Yes ○ No

STEP 10 For Q13, indicate if your HCO is committed to continuously improving strategies for addressing CVD risk in patients with type 2 diabetes. You must select "Yes" on Q12 to be eligible for recognition.


Q13. My organization is committed to continuously improving strategies for addressing CVD risk in patients with type 2 diabetes.

STEP 11

For Q14, which quality improvement (QI) activities for diabetes management has your health care organization engaged during the last year? Select all that apply.

Quality Improvement Activities

The American Heart Association wants to learn more about your efforts to improve quality of health care delivery in your organization during the last year. This information helps us understand trends in health care quality improvement and design programs that meet our participants' needs. Please review the following questions and choose any that may apply.





Under **Tabs** on the righthand side, navigate to the 3rd tab, **"Measure Submission"** tab in the top right corner. For Q15 and Q16, enter Denominator and Numerator data for <u>MIPS</u> <u>#001 - Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%). Patients</u> should be specific to the 2024 calendar year.

		Save Save & Exit 🗮	Tabs	х
		2	Participant Information	- 1
Measure Submission	Save often.		Clinical Practices	- 1
Target: Type 2 Diabetes Data Submission			Measure Submission	_
Measure Numerator/Denominator Submission Award eligibility requires organizations to enter aggregate numerator and denominator values in Q15 and Q16 based on the MIPS population AND one of two Cardiovascular Disease related measures: MIPS #236 Controlling High Blood Pressure or MIPS #438: St Disease. Data should be calculated according to the linked specifications, including all exclusion/exception criteria. Participant infor completed for award eligibility. NOTE: This is an inverse measure, which means it's measuring a negative patient outcome. A smaller numerator in comparison to patient outcome.	tatin Therapy for the Prevention and Treatmer rmation, Clinical Practices, and Measure Subm	nt of Cardiovascular		
DIABETES MEASURE (Required): (Measurement period = January 1 – December 31, 2024)		tab.		
MIPS #001 - Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)				
Denominator: Patients 18 - 75 years of age by the end of the measurement period with diabetes with a visit (in-office or qualifying	g telehealth encounter) during the measureme	ent period.		
Numerater Datients whose most recent HbA1s level (performed during the measurement period) is > 0.0% or is missing, or	dip Patients age 66 and older by the end of the instage 66 and older with at least one encound cute inpatient encounters on different dates were the patient of the instance of the instanc	management period with ter for frailty during the vith an advanced illness		
Poumerator: Patients whose most recent how is level performed during the measurement period) is > 9,0% or is missing, or fo	or Q15 and Q16 based on MIPS #001 .	isurement period.		
Q15. Using MIPS #001 criteria, what is the number of adult patients (18-75 years of age) who had a visit during 2024 and have a diagnosis of diabetes?				
Numerator: Q16. Using MIPS #011 criteria, of the patients with diabetes and a 2024 visit (from Q15), what is the number of patients whose most recent HbA1c level (performed during 2024) is > 9.0% or who had no HbA1c level performed in 2024?				

NOTE: Depending on your answers to Q15 and Q16, you may also be required to answer Q15a.

Question 15a will only appear if your answer to Q15 (the denominator) is less than or equal to 10. If it is, you are required to provide context as to why your denominator is small, and, if applicable, why your overall patient population may be small.

Q15a. REQUIRED – Please provide context on why your organization has ≤10 adult patients meeting the denominator criteria and, if applicable, why your overall patient population may be small. Examples may include unique characteristics of	
your patient demographics or location." (500-character limit).	

STEP 13

For recognition eligibility, you need to enter data for **one CVD measure – option 1 or 2.** Option 1 is questions 17 and 18 (Q17/18) and Option 2 is questions 19 and 20 (Q19/20). You need to enter both Denominator and Numerator data for whichever option you choose.



Option 1 of 2 – Q17 and Q18

Enter Denominator and Numerator data for <u>MIPS #438: Statin Therapy for the Prevention and</u> <u>Treatment of Cardiovascular Disease</u>. Patients should be specific to the 2024 calendar year and reflect all who meet one or more of the four denominator criteria. Please refer to the Data Submission Worksheet for details.

NOTE: The Statin Therapy Denominator/ Numerator questions are <u>identical</u> to Q11 and Q12 in the Check. Change. Control. Cholesterol program form. If you have already completed the Check. Change. Control. Cholesterol form, you can simply copy and paste the measure details. Do <u>not</u> narrow the measure to only patients with diabetes.


CVD Measure #1 (Option 1 of 2):		
MIPS Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease (Measurement period = January 1 – December 31, 2024)		1
Denominator**: All patients who had a visit (in-office or qualifying telehealth encounter) during 2024 ar but be careful not to count them twice – determine patient eligibility in order of each criterion. See exam	MUST complete this	ia (NOTE: A patient may meet 2+ criteria, ation panel.):
 ALL patients, regardless of age, who were previously diagnosed with or currently have a diagnosis of c OR Patients aged 20 to 75 years who have ever had a laboratory result of low-density lipoprotein cholester 	data OR option 2	with or currently have an active diagnosis of
familial hypercholesterolemia; OR 3. Patients aged 40 to 75 years at the beginning of the performance period with Type 1 or Type 2 Diabetes		when or currently have an active diagnosis of
OR 4. Patients aged 40 to 75 years at the beginning of the performance period with a 10-year ASCVD risk score		
**All patients who meet one or more of the above criteria would be considered at high risk for cardiovasc	ular events under the ACC/AHA guidelines.	
Numerator: Patients who are actively using or who receive an order (prescription) for statin therapy at an	ny point during the measurement period.	
NOTE: The Statin Therapy Denominator / Numerator questions are identical to Q13 and Q14 on the patients with diabetes.	Check. Change. Control. Cholesterol program for	m. Do NOT narrow measure to only
Denominator: Q17. Identify the number of patients in EACH of the above four risk groups. What is the sum of patients in all four risk groups? Avoid double-counting patients who fall into more than one risk group. NOTE: All four risk groups must be factored into the final denominator total.	Enter data b	
You must use the MIPS #438 measure criteria as specified – using a different measure, using a custom dee eligibility.	finition of at-risk patient MIPS #438	criteria.
Numerator: Q18. Using MIPS #438 criteria, of the patients given in Question 17, how many were prescribed or were actively using statins at any point during 2024?		

Option 2 of 2 – Q19 and Q20

Enter Denominator and Numerator data for <u>MIPS #236: Controlling High Blood Pressure</u>. Patients should be specific to the 2024 calendar year. Please refer to the Data Submission Worksheet for details.



NOTE: The controlling high blood pressure Denominator/Numerator questions are <u>identical</u> to Q4 and Q5 on the Target: BP program form. If you have already completed the Target: BP form, you can simply copy and paste the measure details. Do <u>not</u> narrow the measure to only patients with diabetes.



STEP 14

When all data are entered, check the **"Data Entry Complete"** checkbox and click the **Save & Exit** button at the top of the Participant Information page.

Data may be edited at any time. All recognition awards will be based on a "snapshot" of data available in the platform on May 16, 2025, at 11:59 p.m. ET.